Follow
CAR-T biomarker discovery
Chimeric antigen receptor (CAR) T cell therapy is an emerging form of immunotherapy which engineers a patient's immune cells to better identify and kill cancer cells. While CAR-T cell therapy can cure hard-to-treat cancers, only a small proportion of patients respond favorably. Identifying biomarkers, biological molecules that be predict how a person may respond to a treatment, can help doctors determine which patients will benefit from this therapy. Because CAR-T cell therapy is costly and time-consuming, there is an effort to promote research focused on discovering biomarkers to manage treatment.
NOV 16, 2021 | 8:00 AM
Date: November 16, 2021 Time: 8:00am (PDT), 11:00am (EDT) The unique suppressive function of regulatory T cells (Treg cells) makes them an interesting target cell population to study. In rec...
NOV 04, 2021 | 8:00 AM
Date: November 4, 2021 Time: 8:00am (PDT), 11:00am (EDT) The promise of tissue clearing techniques in combination with 3D-immunofluorescence (IF) microscopy is revolutionary. Complex biologi...
NOV 03, 2021 | 7:00 AM
Date: November 3, 2021 Time: 7:00am (PDT), 10:00am (EDT) The reconstitution of a fully functional human immune system in mouse after engraftment of purified hCD34+ hematopoietic cells provid...
OCT 07, 2021 | 11:55 PM
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
OCT 06, 2021 | 12:00 PM
Advancements in immuno-oncology have been moving at an ever-quickening pace. From the development of new CAR-T therapies to a better understanding of the mechanism of action of monoclonal an...
JUL 22, 2021 | 5:00 PM
Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this thera...
JUN 02, 2021 | 9:00 AM
Over the past 25 years, Luminex’s xMAP® Technology has emerged as the worldwide leader in bead-based multiplexing. The new xMAP® INTELLIFLEX platform combines the proven perfor...
APR 06, 2021 | 8:00 AM
Date: April 06, 2021 Time: 8:00am (PST), 11:00am (EST) The discovery of the reproducibility crisis has called into question a worrying number of scientific results over the last few years. In...
FEB 03, 2021 | 8:00 AM
Date: February 3, 2021 Time: 8:00am (PST), 11:00am (EST) This introduction webinar will provide you with an overview of the general immuno-oncology (IO) research field...
JUL 22, 2020 | 10:00 AM
DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
JUN 17, 2020 | 1:30 PM
The COVID-19 pandemic has resulted in over 7 million cases and more than 428000 cases to date. While public health interventions and social distancing measures have been effective in slowing...
JUN 17, 2020 | 7:30 AM
Coronavirus disease 2019 (Covid-19) is a global pandemic that has impacted the lives of the entire world’s population. Accurate and effective testing mechanisms to identify those with...
JUN 03, 2020 | 7:00 AM
Dr. Koenitzer will present an overview of her current research in immune suppression. After a brief introduction to the MILLIPLEX® multiplex immunoassay portfolio, Dr. Koenitzer will dis...
